CITATION REPORT List of articles citing

A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA from 2007-2013

DOI: 10.1177/2168479016646809 Therapeutic Innovation and Regulatory Science, 2016, 50, 639-647.

Source: https://exaly.com/paper-pdf/64170295/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Industry Perspective of Pediatric Drug Development in the United States: Involvement of the European Union Countries. <i>Therapeutic Innovation and Regulatory Science</i> , 2018 , 52, 49-56	1.2	4
7	Cardiovascular Paediatric Medicines Development: Have Paediatric Investigation Plans Lost Heart?. <i>Pharmaceutics</i> , 2020 , 12,	6.4	3
6	Gap between pediatric and adult approvals of molecular targeted drugs. <i>Scientific Reports</i> , 2020 , 10, 17145	4.9	4
5	Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review. Drugs - Real World Outcomes, 2020 , 7, 97-107	2.2	5
4	Guidance for pediatric use in prescription information for novel medicinal products in the EU and the US <i>PLoS ONE</i> , 2022 , 17, e0266353	3.7	O
3	Does the EU and US Paediatric legislation improve authorisation availability of medicines for children in other countries?.		О
2	Mandatory requirements for pediatric drug development in the EU and the US for novel drugs a comparative study. 9,		0
1	Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics. 2023 , 15,		О